Amyotrophy inhibiting composition

一种肌肉萎缩、组合物的技术,应用在药物组合、肌肉系统疾病、神经肌肉系统疾病等方向,达到抑制肌肉萎缩、改善肌肉量下降的效果

CN110234334AActive Publication Date: 2019-09-13OTSUKA PHARM CO LTD
6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2019-09-13

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Provided is an amyotrophy inhibiting composition that comprises one or more kinds of peptides as active ingredient(s), said peptides being selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP and NPK, a group consisting of dipeptides containing F, and the group consisting of dipeptides DI, IY, YN and NP.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] This application claims priority based on Japanese Patent Application No. 2016-236099, and the entire contents thereof are hereby incorporated by reference into this specification.

[0002] The present invention relates to a muscle atrophy inhibiting composition containing dipeptide or tripeptide as an active ingredient. Background technique

[0003] It has been reported that, for humans, the muscle mass decreases at a rate of about 5% every 10 years after the age of 30, and the decrease rate of the muscle mass accelerates after the age of 60. Regarding the atrophy of skeletal muscle, in addition to being seen in age-related sarcopenia, it can also be caused by inactivity (disuse, bed rest, plaster immobilization) or weightlessness (outer space) , Denervation, disease (cancer, AIDS (AIDS), diabetes, etc.), malnutrition. A phenomenon that occurs in all muscle atrophy is muscle fiber atrophy (decrease in muscle cross-sectional area) caused by a decreas...

Examples

Embodiment 1

[0086] Muscle atrophy inhibition in mouse skeletal muscle cell lines

[0087] Mouse skeletal muscle cell line (C2C12) was incubated in DMEM supplemented with 10% FBS at 37°C, 5% CO 2Conditions for subculture and maintenance. Ordinary medium was prepared by adding 12.5 mL of HEPES (4-hydroxyethylpiperazineethanesulfonic acid) (gibco), 5.5 mL of penicillin-streptomycin (gibco) and fetal calf serum ( FBS, Sigma-Aldrich) 55mL. In addition, a differentiation medium was obtained by adding 12.5 mL of HEPES, 5.5 mL of penicillin-streptomycin, and 12.5 mL of bovine serum (HS, SAFC Bioscience) to DMEM.

[0088] Convert C2C12 to 5×10 5 Cells / dish were inoculated into 6 cm dishes (Asahi Techno Glass Corporation), and cultured in normal medium for 2 days. Thereafter, differentiation induction was performed in a differentiation medium. 5 days after the start of induction, the medium was replaced with the addition of each peptide (17 kinds: DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, N...

Embodiment 2

[0091] Inhibition of Muscle Atrophy in Model Animals